about
Application of metabolomics in drug resistant breast cancer researchDoping control using high and ultra-high resolution mass spectrometry based non-targeted metabolomics-a case study of salbutamol and budesonide abuseBody mass index: Has epidemiology started to break down causal contributions to health and disease?Data-handling strategies for metabonomic studies: example of the UHPLC-ESI/ToF urinary signature of tetrahydrocannabinol in humans.Metabolomic analysis of human disease and its application to the eye.Eating at the table of another: metabolomics of host-parasite interactions.Metabolomics applied to urine samples in childhood asthma; differentiation between asthma phenotypes and identification of relevant metabolites.Metabolomics of ApcMin/+ mice genetically susceptible to intestinal cancerImproved blood tests for cancer screening: general or specific?Metabolomics of gastric cancer metastasis detected by gas chromatography and mass spectrometry.Metabolomics: a tool for the diagnosis of GH deficiency and for monitoring GH replacement?Computational strategies for a system-level understanding of metabolism.Metabolic characterization of triple negative breast cancer.In situ drug and metabolite analysis [corrected] in biological and clinical research by MALDI MS imaging.Metabolic alterations in the sera of Chinese patients with mild persistent asthma: a GC-MS-based metabolomics analysis.Global Prioritization of Disease Candidate Metabolites Based on a Multi-omics Composite Network.A Systematic Review of Health Economic Evaluations of Diagnostic Biomarkers.Biomarkers intersect with the exposome12-months metabolic changes among gender dysphoric individuals under cross-sex hormone treatment: a targeted metabolomics study.Review of mass spectrometry-based metabolomics in cancer research.Deconvoluting the 'omics' for organ transplantationDiscrimination of pancreatic cancer and pancreatitis by LC-MS metabolomics.Emerging molecular biomarkers--blood-based strategies to detect and monitor cancer.Metabolomics and surgical oncology: Potential role for small molecule biomarkers.Metabolomics in urogenital cancer.Biofluid metabonomics using (1)H NMR spectroscopy: the road to biomarker discovery in gastroenterology and hepatology.Novel methodologies in metabolic profiling with a focus on molecular diagnostic applications.Mass spectrometry strategies for clinical metabolomics and lipidomics in psychiatry, neurology, and neuro-oncology.Oncometabolomics in cancer research.Cancer metabolomics in basic science perspective.Coefficient of Variation, Signal-to-Noise Ratio, and Effects of Normalization in Validation of Biomarkers from NMR-based Metabonomics Studies.Amino acid profiles as potential biomarkers for pediatric cancers: a preliminary communication.Metabolomics applications in precision medicine: An oncological perspective.Metabolomic Biomarkers of Prostate Cancer: Prediction, Diagnosis, Progression, Prognosis, and Recurrence.The potential biomarkers of drug addiction: Proteomic and metabolomic challenges.Proteomic and metabolomic strategies to investigate HIV-associated neurocognitive disordersMetabolomic and Lipidomic Profiling Identifies The Role of the RNA Editing Pathway in Endometrial Carcinogenesis.The Impact of GFP Reporter Gene Transduction and Expression on Metabolomics of Placental Mesenchymal Stem Cells Determined by UHPLC-Q/TOF-MS.Mendelian randomization: where are we now and where are we going?Neuronal metabolomics by ion mobility mass spectrometry in cocaine self-administering rats after early and late withdrawal.
P2860
Q26866291-A36BD3D9-79B8-43AD-BB94-58F56EAF83C0Q28533600-415E156D-D1C1-4DE7-840B-ABA7BD9D34F4Q30248778-ECB9C273-5846-4226-A92F-18BA317CAD54Q30658279-18ED2877-1F61-4315-A7DF-154BFAB6387EQ33631499-423DF465-9773-4909-B961-9B886DEDDF15Q33671828-E60275EC-A20C-4CE8-8109-3A8F719D1E24Q33862915-3A18144A-E855-454B-860A-699DF94D96E7Q33904600-ABEE41AF-0102-4F84-A1C6-F3A585BD5CFDQ34086617-8C65ABC0-5C68-42AF-B081-FA27FC0F14EBQ34406520-83D2EB1C-469D-4254-B569-C6A9FFF6D7C4Q34419559-8585191F-8F67-408B-9C9C-AAC1F4279097Q34785750-28A265FE-6015-4365-AAC8-A502ECF60D8DQ34967995-99461017-3E55-4547-A66D-DC0CEA72CB13Q35191571-9E3D8109-92B8-480A-B859-5F5942200707Q36254528-4FF67D7C-CF11-4C25-8D95-A6944E0FA393Q36310177-BB481CE0-C318-4D68-B233-41E9DC1D9721Q36541715-E386C2E4-6612-4703-AE3A-CD76337AA9D1Q36607005-F36D75BC-733D-453C-9A7D-C9AFA81B06B7Q37408529-561A10D1-97AA-49C5-854B-E909F8620CD8Q37550758-FD99D75E-CC19-4653-85DB-16D8663B927DQ37567360-CB8804DF-5EE6-417F-AD0D-56281F3FD21AQ37733470-4C80AF4B-1562-40E3-9073-F8A4220071C0Q37848663-C11AA182-EB1E-4E5F-8C71-008941CA5E62Q37852648-BE526E88-5D98-4552-AF94-22F62E8D5F4EQ37867682-1F95ECE3-2A3B-48E4-B713-A6D9CCFBD9AAQ37989165-71A600BE-7563-4F0E-B552-379D8F2C4749Q38019000-9EE60D88-625E-4375-BB90-391F86E9BA78Q38120648-06D1961A-3F7F-4FCA-BF3A-7C2AB51E8FEAQ38132912-84C23BE7-9D14-43CC-A276-8564AA75DDE6Q38335800-35C2D68E-D4D7-46FD-BCA6-123D6694BCECQ38425546-AE1A4B19-23FA-47E6-B12D-B634E7A06D00Q38645050-BD84486A-3D8A-41C2-AEA8-DAB9BFBD4ABBQ38689857-60CAC215-ED32-467F-A9ED-63E286022133Q38838580-D61D2E6E-DB9A-413B-82DA-D078F9E234E0Q38850141-153B9D55-7F9C-416C-B126-24A604EFB63EQ40663824-69F10621-1E7F-49E0-908B-D773C0838B66Q41459821-5A5E742F-99AA-434D-B46E-3FDB6C115F02Q47111218-A0E8DDD3-B021-4811-BC09-77A2EE4C760BQ48456096-C7E93201-4EE7-4C25-84C9-5CD0591A76C4Q48797991-7975D0E3-8107-4E02-9088-E6740397667D
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 April 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Metabolomics: moving to the clinic.
@en
Metabolomics: moving to the clinic.
@nl
type
label
Metabolomics: moving to the clinic.
@en
Metabolomics: moving to the clinic.
@nl
prefLabel
Metabolomics: moving to the clinic.
@en
Metabolomics: moving to the clinic.
@nl
P2860
P1476
Metabolomics: moving to the clinic.
@en
P2093
Anders Nordström
Rolf Lewensohn
P2860
P2888
P356
10.1007/S11481-009-9156-4
P577
2009-04-28T00:00:00Z